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Abstract
Sirtuin1 deficiency or reduced activity comprises one of the hallmarks of diseases as diverse as chronic cardiovascular, renal, and
metabolic, some malignancies, and infections, as well as aging-associated diseases. In a mouse model of endothelium-limited
defect in sirtuin 1 deacetylase activity, we found a dramatic reduction in the volume of endothelial glycocalyx. This was
associated with the surge in the levels of one of key scaffolding heparan sulfate proteoglycans of endothelial glycocalyx,
syndecan-4, and specifically, its extracellular domain (ectodomain). We found that the defect in endothelial sirtuin 1 deacetylase
activity is associated with (a) elevated basal and stimulated levels of superoxide generation (via the FoxO1 over-acetylation
mechanism) and (b) increased nuclear translocation of NF-kB (via p65 over-acetylation mechanism). These findings laid the
foundation for the proposed novel function of sirtuin 1, namely, the maintenance of endothelial glycocalyx, particularly manifest
in conditions associated with sirtuin 1 depletion. In the forthcoming review, we summarize the emerging conceptual framework
of the enhanced glycocalyx degradation in the states of defective endothelial sirtuin 1 function, thus explaining a broad footprint
of the syndrome of endothelial dysfunction, from impaired flow-induced nitric oxide production, deterrent leukocytes infiltration,
increased endothelial permeability, coagulation, and pro-inflammatory changes to development of microvascular rarefaction and
progression of an underlying disease.
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Introduction
Sirtuin family (SIRT) of protein and histone deacetylases is
represented by seven mammalian SIRT proteins (SIRT1-
SIRT7). Sirtuins have been the subject of multitude of inves-
tigations which have demonstrated that SIRT proteins are re-
sponsible for diverse cell functions and are capable of protec-
tion against several diseases like diabetes, cancer, or cardio-
vascular diseases [50, 53, 63]. There are approximately 500
different known target proteins for SIRT-deacetylation.
SIRT1, the founding member of the family [39], is an NAD-
dependent deacetylase participating in chromatin regulation
(by deacetylating H3K9, H3K56, H4K16, H1K26,
SUV39H1, p300, and PCAF); DNA repair (HDAC1,
PARP1, p53, KU70, NBS1, E2F1, RB, XPA,WRN, survivin,
β-catenin, MYC, NF-κB, and TOPBP1), and cell metabolism
(PGC1α, FOXO1, FOXO3A, FOXA2, CRCT1, CRCT2,
PPARα, PPARγ, LXR, FXR, RARβ, SREBP1C, SREBP2,
HNF4α, HIF1α, HIF2α, CREB, NKX2–1, STAT3, TFAM,
MYOD, NHLH2, UCP2, TSC2, eNOS, LKB1, SMAD7,
AKT, ATG5, ATG7, ATG8, 14-3-3ζ, PGAM1, ACECS1,
PTP1B, and S6K1) [17]. Studies of the role of SIRT1 in en-
dothelial cells were significantly accelerated by the creation of
SIRT1endo-/- mice [97] which demonstrated that this
deacetylase participates in angiogenesis.
We have recreated and further explored this mouse model
[22, 76, 123] to demonstrate development of premature senes-
cence of endothelial cells, rarefaction of renal peritubular mi-
crovascular network, diastolic dysfunction, reduced expres-
sion of the membrane-tethered matrix metalloproteinase
MMP-14, defective acetylcholine-induced vasorelaxation,
and propensity toward tubulointerstitial fibrosis—all hall-
marks of developing endothelial cell dysfunction. The fact
that dysfunctional endothelial cells can trigger fibrosis alluded
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to the possibility of secretory products of such cells inducing
fibroblast activation and prompted us to perform an unbiased
proteomic screen of the secretome of SIRT1-deficient vis-à-
vis control endothelial cells isolated from renal microvascula-
ture [70–72]. Among various differentially expressed proteins
in the aberrant secretome, syndecan-4 ectodomain was prom-
inently present [73]. Syndecan-4 is a major proteoglycan of
endothelial cell glycocalyx. Hence, in parallel studies of
SIRT1endo-/- mice, Song et al. [110] demonstrated by dual-
fluorophore dilution technique that endothelial glycocalyx of
these mice is disintegrated. Based on these findings, we de-
duced that SIRT1may have another, yet unidentified, function
in maintaining endothelial glycocalyx integrity. This review
summarizes our and others’ most recent findings on this sub-
ject. It should be noted that this review is not intended to
illustrate the entire spectrum of glycocalyx components and
functions, rather it is limited to exhibit our hypothesis that
SIRT1-induced deacetylation is crucial for the maintenance
of endothelial glycocalyx.
Endothelial glycocalyx
The endothelial glycocalyx (EG) can be defined as a layer
with a high amount of carbohydrates which covers the vascu-
lar endothelium. It is coated with a carbohydrate-rich layer of
an average thickness of 0.2–2 um and consisting of hyaluronic
acid (HA) cords reaching 1 um in length, heparan sulfate (HS)
chains reaching in length 200 nm, and comprising 50–90% of
endothelial glycosaminoglycans, with an admixture of
dermatan, keratan, and chondroitin sulfates [103]. The high
degree of sulfation of these components provides EG with a
net negative charge [103]. Among those mentioned glycos-
aminoglycans, the most common ones are HS followed by
chondroitin sulfate and HA, although the levels of each gly-
cosaminoglycan depend highly on various current stimuli
[99]. HA differs from the other glycosaminoglycans, since it
has no linkage to a core protein and it binds to the osteopontin
receptor CD44 [87]. With the newest technique, the use of
super-resolution optical microscopy (STORM), the study
group of Fan et al. was able to visualize HA as long molecules
forming a hexagonal network which covers the endothelial
lumen. HS, on the other hand, was visualized as a shorter
molecule with a straight positioning to the cell surface [37].
The HA network plays a major role in the stability and func-
tion of the EG, as passage through the EG is regulated by HA
[126]. Moreover, endothelial mechanosensing and the preser-
vation of endothelial quiescence are in need of the presence of
HA [98]. HS acts mainly as a mechanosensor arbitrating the
regular release of NO as shown by Florian et al. [38].
The membrane-tethered scaffold for these glycosaminogly-
cans consists of two families of proteoglycans: syndecans 1–4
(single membrane-spanning domain) and glypicans 1–6
(glycosylphosphatidylinositol-anchored) [103]. Since there
are multiple ways of modifications of the glycosaminoglycan
chains, the diversity of the glycosaminoglycans results in the
alternation of specific protein binding, in the alternation of
protein functions, and in the modulation of vascular perme-
ability [103]. Consequently, the EG creates a dynamic balance
between itself and the luminal components, alternating its
composition and thickness [103].
In addition, several glycoprotein families (selectins,
integrins, and immunoglobulins) are present in EG. Their
main role of action is the regulation of cell recruitment from
the bloodstream. Selectins present in EG are E-selectin and P-
selectin with their main action in the field of cell interaction
between leukocytes and the endothelium [111]. Especially E-
selectin is ovexpressed in endothelial cells after stimulation by
cytokines [57]. Integrins can be described as molecules com-
posed of non-covalently bound α and β subunits [103].
Luminally endothelial cells express integrin αVβ3, mediating
the cell interaction between the endothelial cell and platelets
[9]. The other integrins expressed at EG are associated with
binding to the basement membrane and interact with laminin,
fibronectin, and collagen [103]. The immunoglobulins are di-
vided in a cytoplasmic, a transmembrane, and an extracellular
part, acting as ligands for integrins and mediate leukocyte
homing to the endothelium [103].
EG provides a repository for diverse biologically active
molecules, as it incorporates and interacts with extracellular
superoxide dismutase (SOD), xanthine oxidoreductase, inter-
leukins, like IL2, IL5, IL7, IL8, and IL12, low density lipo-
protein (LDL) and LDL lipase, bFGF, VEGF, and TGF-beta,
and several regulators of coagulation, like antithrombin III,
heparin cofactor II, and tissue pathway factor inhibitor
[103]. EG is a guardian of endothelial cell homeostatic func-
tions. Due to its unique location, this structure provides a
passive barrier to water and solutes (regulation of vascular
permeability), and to the interaction between circulating cells
and the endothelial cells (regulation of leukocyte trafficking)
[5]. It also serves as a sensor of mechanical forces, such as
shear stress and pressure, and shields cell surface receptors
preventing their hyper-activation [5, 40].
This structure is, however, quite vulnerable and tends to
disintegrate under the influence of various stressors, such as
endotoxins, ischemia/hypoxia/reperfusion, oxidative stress,
among others [107]. It also leads to hyper-activation of plasma
membrane receptors left exposed to respective unhindered
ligands, with further activation of endothelial cells and prop-
agation of danger signaling [27]. The degradation of EG is
also accompanied by the compromised anti-coagulant proper-
ties of this layer, increased endothelial permeability, reduced
antioxidant barrier, enhanced transmigration of pro-
inflammatory cells, impaired mechanotransduction, and endo-
thelial nitric oxide synthase activity [2, 27, 107]. In acute
kidney injury induced by ischemia/reperfusion, sepsis, and/
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or kidney transplantation, EG is impaired both in experimental
animals and in humans [19, 47, 84, 95, 108, 109, 134].
Another condition frequently associated with the degrada-
tion of EG is diabetic nephropathy. Deckert and colleagues
[25] were the first to show that the de novo synthesis of hep-
aran sulfate was reduced in fibroblasts isolated from diabetes
patients with albuminuria, but not from those without albu-
minuria or control healthy subjects, and formulated a hypoth-
esis that the loss of EG is a prerequisite for the developing
diabetic nephropathy. Recently, upregulation of endothelin-1
in diabetes was incriminated in the induction of heparanase in
podocytes, resulting in impairment of glomerular EG [43].
This is in agreement with studies by different investigators
who have demonstrated the loss of glycocalyx integrity in
diabetes mellitus [85, 90, 91]. Considering the role of EG in
endothelial cell function and dysfunction [133], its putative
dependence on SIRT1 expression and activity, both impaired
in the above pathologic conditions, gains additional import.
Our recent unbiased proteomic studies of microvascular endo-
thelial cells expressing deacetylation-deficient SIRT1 have
revealed upregulation of syndecan-4, and, specifically, its
ectodomain. Scenarios tentatively explaining this finding are
briefly summarized below.
NF-κB as a target for SIRT1 deacetylation
It has been well-documented that SIRT1 is a negative regula-
tor of inflammation, in part due to its effects on nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-kB), one
of the target proteins for SIRT1-deacetylation [130]. In mam-
mals, the following members of the NF-κB family have been
described: NF-κB1 (p105/p50), NF-κB2 (p100/p52), RelA
(p65), RelB, and c-Rel [10, 45]. NF-κB is known for its reg-
ulatory effects on transcription of DNA, cytokine production,
and cell survival [13]. NF-κB usually forms dimers, which is
necessary for binding DNA. One typical structure of NF-κB is
the p50-p65 dimer (NF-κB1/RelA) [20].
In order to unfold its transcriptional activity, NF-κB needs
to translocate into the nucleus. In an inactive state NF-κB
remains in the cytoplasm and is bound to specific inhibitors,
the Iκ-B proteins (IκBa, IκBb and IκBg), which, in turn, bind
to the Rel homology domain (RHD) of NF-κB and therefore
interfere with its nuclear translocation [10, 121]. Hence the
activation of NF-κB is linked to the release of its inhibtors.
Pro-inflammatory cytokines induce the activation of the IκB
kinase complex, releasing NF-κB from its inhibitors and con-
sequently leading to NF-κB nuclear translocation [10, 121].
NF-κB is a target protein for SIRT-deacetylation (Fig. 1).
In fact, SIRT1 binds to p65 protein disabling its transcriptional
activity by deacetylating p65 at Lys310 [12, 131]. Consistent
with this, induction of SIRT1 results in the inhibition of
NF-κB-dependent inflammatory pathway [93, 131] and vice
versa, which reduced activation of SIRT1 that leads to en-
hanced NF-κB signaling [58].
This relation between SIRT1 and NF-κB becomes a main
concern when SIRT1 is inhibited exclusively in the endothe-
lium, which has been demonstrated to represent an excellent
model of global endothelial dysfunction [123]. In case of
SIRT1 inhibition in endothelial cells, the increased NF-κB
signaling could lead to the enhanced degradation of the EG
in part due to induced shedding of EG proteoglycans and
activation of heparanases.
Syndecan-4: a proteoglycan
of the endothelial glycocalyx
Proteoglycans represent one of the essential components of
the EG, which is also true for the underlying basement mem-
brane of endothelial cells [125]. Among those proteoglycans
there is the family of syndecans. Syndecans are transmem-
brane receptors with autonomous and combined signal capac-
ity which have mostly heparan sulfate glycosaminoglycans
covalently bound to their extracellular domain [23, 24, 36].
The family of syndecans includes four members: syndecans1–
4. Syndecan-1 is typically found in epithelial, endothelial, and
plasma cells, whereas syndecan-2 is rich in endothelial and
mesenchymal cells and syndecan-3 is mostly found in neural
crest-derived cells [64, 118]. Syndecan-4, however, is the only
family member with a ubiquitous distribution and is highly
expressed in endothelial and epithelial cells in the kidney and
other organs [125]. In cultured endothelial cells, inflammatory
mediators such as lipopolysaccharide (LPS) and interleukin
1β (IL-1β) syndecan-4 expression showed a rapid increase,
while Syndecan-1 and -2 expression decreased and syndecan-
3 was unaffected [125] implying that this proteoglycan may
represent a key proinflammatory sensor of endothelial cells.
Syndecan-4 is a target of TNF-alpha-induced matrix
metalloproteinase-9 leading to degradation of glycocalyx
[101]. Syndecan-4 has been found to counteract effects of
eNOS and serve as an enhancer of angiopoitin-2 secretion
leading to antiangiogenesis [56]. The spectrum of Syndecan-
4 signaling properties has been comprehensively reviewed
[34]:
One of the main functions of syndecan-4 is to serve as a co-
receptor for heparin-binding growth factors, such as fibroblast
growth factors (FGFs), vascular endothelial growth factors
(VEGFs), and platelet-derived growth factors (PDGFs), coor-
dinating the extracellular space distribution of these growth
factors [119].
In order to understand the signaling properties and the array
of functions of syndecan-4, it is necessary to look separately at
the different domains of this molecule: the extracellular, the
transmembrane, and the intracellular. The cleavage and shed-
ding of the syndecan-4 extracellular domain, also termed
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ectodomain, play an important role in mediation of its extra-
cellular signaling. The shed syndecan-4 ectodomain regulates
cellular adhesion to the surrounding matrix and is capable of
orchestrating the direct contact of cells with ECM proteins
[34, 122]. Shedding of this domain leads to the dissipation
of extracellular SOD, heparin-binding growth factors, and a
host of other biologically active substances mentioned above,
which are concentrated within EG. The loss of their surface
gradient compromises cellular defense against oxidative
stress, reduces growth and pro-survival signaling, and impairs
interactions with other cells [34].
At the transmembrane site, syndecan-4 unfolds three sig-
naling functions: it non-covalently clusters into sodium dode-
cyl sulfate (SDS)-resistant oligomers (the hallmark of lipid-
rich domains, such as caveolae) which harbor diverse signal-
ing cascades; it balances the interaction between growth fac-
tors, their cognate receptors, and other cell membrane recep-
tors; and it serves as a direct link between the ECM and intra-
cellular signaling proteins [34].
Intracellular domain of syndecan-4 and one of its major
binding partners, synectin, facilitates the binding of Rho gua-
nidine dissociation inhibitor 1 (RhoGDI1) and serves to insu-
late and decrease the activity of Rho family GTPases that are
incorporated into the syndecan-4–synectin–RhoGDI1 com-
plex at the cell membrane [33] in the absence of growth factor
stimulation. Upon stimulation by growth factors, syndecan-4
reverses the described decrease in the activity of Rho family
GTPases through its ability to bind and activate PKCα. PKCα
in turn phosphorylates RhoGDI1 at Ser96, which allows the
release of sequestered RhoG and Rac1 [34].
The role of proteoglycans and one of their major members,
syndecan-4, in a variety of pathologic processes, has been a
subject of a score of investigations. After skin injury, the ex-
pression of syndecan-4, on the one hand, is temporarily de-
creased in those keratinocytes, which migrate into the wound,
and, on the other hand, it is increased in those keratinocytes,
which proliferate at the wound margins, with specific increase
in fibroblasts within the forming granulation tissue [32, 41].
Mice with a disrupted syndecan-4 gene have delayed healing
of skin wounds and impaired angiogenesis in the granulation
tissue [28]. Furthermore, it has been shown that syndecan-4−/−
mice have an increased mortality rate after a myocardial in-
farction due to cardiac rupture. Those cardiac events are asso-
ciated with reduced inflammatory reaction and impaired gran-
ulation tissue formation due to reduced numbers of infiltrating
leukocytes, fibroblasts, myofibroblasts, macrophages, and
capillary vessels [80]. In addition, mice deficient in
syndecan-4 have an increased susceptibility to LPS-
injections manifested in increased mortality [55]. On this
background, it has recently been reported that syndecan-4
knockout in mice protects against tubulointerstitial fibrosis
apparently due to the reduction of tissue transglutaminase ac-
tivity [106]. This finding has been substantiated by the study
ofWee et al. showing the activation of transglutaminase 2 and
syndecan-4 by tissue-resident natural killer cells in a model of
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Fig. 1 Interaction between
Sirtuin1 and NF-κB, Sirtuin1
deacetylates p65 at Lys310
disabling the transcriptional
activity of p65 and results in the
proteosomal degradation of p65.
If SIRT1 is inhibited or deficient,
p65 remains in its acetylated
form, and therefore p65 is able to
release itself from IκB and
translocates to the nucleus. In the
nucleus p65 induces the
transcription of syndecan-4 and
reduces the transcription of
Sirtuin1
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with a wealth of the abovementioned critical functions of
syndecan-4, the question of the mechanism responsible for
its reported pro-fibrotic action in renal injury requires
elucidation.
It has been argued that these harmful effects could be due,
at least in part, to the effects of its extracellular ectodomain
[115], rather than the effects of the whole syndecan-4 mole-
cule. In fact, the mouse knockout model of syndecan-4 defi-
ciency has been generated by deleting the exon encoding the
extracellular domain [106]. The physiology of the syndecan-4
ectodomain is noteworthy because it is highly distinct from
functions of the whole molecule, as mentioned previously.
The ectodomain of syndecan-4 promotes collagen cross-
linking and induces innate immunity signaling, stimulates im-
mune cell infiltration, therefore exhibiting a central role in
chemotaxis [114]. The release of the ectodomain is induced
by pro-inflammatory stimuli, like, for instance, in the event of
tissue injury [74, 114]. On the other hand, maintenance mech-
anisms exist to prevent the excessive release of the
ectodomain. One important maintaining factor is endothelial
SIRT1.
SIRT1 exhibits an important functional role in maintaining
homeostasis of endothelial cells, and in reverse, SIRT1 defi-
ciency in endothelial cells leads to a long list of endothelial
abnormalities, as mentioned above. One of these abnormali-
ties is the loss of EG. The expression of the EG is dramatically
reduced in SIRT1endo-/- mice, a model of global endothelial
dysfunction [73, 123]. In addition, syndecan-4 ectodomain is
highly upregulated in this model of global endothelial dys-
function. In other words, the impairment of EG goes hand in
hand with an impaired whole syndecan-4 molecule, leading to
an increased amount of shed syndecan-4, allowing the
syndecan-4 ectodomain to be released and to participate in
fibrogenesis. How does this occur?
Interestingly, syndecan-4 is a NF-κB target gene [115]. As
described above, SIRT-1 deacetylates p65 protein preventing
the nucleus translocation of NF-κB [12, 131]. Hence, in-
creased SIRT-1 activity results in the inhibition of NF-κB-
dependent inflammatory reactions [93, 131] while the de-
creased SIRT-1 activity enhances NF-κB signaling [58].
Indeed, our studies showed that the nuclear translocation of
NF-kB is increased and syndecan-4 transcripts are elevated in
SIRT1endo-/- mice, whereas the expression of syndecan-4 on
the surface of renal microvascular endothelial cells isolated
from SIRT1endo-/- mice was found to be decreased in parallel
with increased syndecan-4 ectodomain abundance in the
secretome of these cells and in the interstitium of the kidneys
undergoing fibrotic transformation after an experimental in-
sult [73]. Apparently, despite the elevated message level,
syndecan-4 ectodomain is shed from the endothelial surface
of SIRT1endo-/- mice, thus depleting the major scaffolding
component of EG. These relations between SIRT-1 and
NF-κB may explain the degradation of the EG in
SIRT1endo-/- mice, resulting in a higher amount of shedding
of syndecan-4 (Fig. 2).
In addition to that, we have observed that renal microvas-
cular endothelial cells isolated from SIRT1endo-/- mice have
an increased basal and stimulated superoxide generation. This
finding is consistent with the known effect of SIRT1 to
deacetylate Forkhead box O (FoxO1) DNA-binding proteins.
The deacetylated form is necessary for the post-translational
modification of this transcription factor which is needed for its
active modification and higher cellular defense against oxida-
tive stress [15, 83]. In turn, increased oxidative stress in renal
microvascular endothelial cells of SIRT1endo-/- mice further
leads to the activation of a redox-sensitive domain of the
sheddase cleaving the ectodomain of syndecan-4, disintegrin,
and metalloproteinase domain-containing protein 17
(ADAM-17) [128]. Activation of ADAM-17may be ultimate-
ly responsible for shedding of syndecan-4 [60].
Sheddases targeting the endothelial
glycocalyx
Increased shedding of the EG components has been linked to
the pathogenesis of a wide variety of diseases. There is data
demonstrating the degradation of the EG in the course of
hypertensive diseases or in the hemolytic uremic syndrome,
as judged by the detection of increased amounts of shed hep-
aran sulfates, syndecans, and hyaluronan into the bloodstream
or the urine [8]. In a cohort study, it has been shown that
trauma patients demonstrated a higher amount of shed EG
components (syndecan-1, hyaluronic acid). The higher
amount of shedding has been linked to a lower plasma colloid
osmotic pressure, indicating a correlation between low plasma
colloid osmotic pressure and degradation of the EG [100]. A
different study with a similar approach disclosed the correla-
tion between an increased release of atrial natriuretic peptide
and higher plasma levels of EG components (hyaluronan,
heparan sulfate, and syndecan-1) during hypervolemia [18].
There is also a hypothesis that the degradation of the EG
manifests as an important step in the pathogenesis of malaria.
Hempel et al. proposed that infected erythrocytes bind to the
outer layer of the EG leading to increased shedding and
allowing the parasites to interact with proteins in the deeper
layer of the EG [51].
Shedding of the EG also causes biologically active compo-
nents and proteins bound to the endothelial surface layer to
disappear from the close vicinity of the luminal vascular sur-
face, with the consequent loss of their respective local actions
and gain of systemic cytokine-like effects [6]. For example,
the loss of xanthine oxidoreductase at the endothelial surface
leads to decreased production of uric acid [4], less lipoprotein
lipase limits the activity of the lipid metabolism which further
limits the number of chylomicrons, and free fatty acids to
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parenchymal cells [62, 105]. Shedding of syndecan-4, as de-
scribed in detail previously, provides a good example for the
acquisition by the ectodomain of systemic effects.
Investigations of the shedding of the EG have been the
target of a score of studies, and the results of these studies
suggest that matrix metalloproteinases (MMPs) are the major
contributors to cleaving scaffolding molecular components of
the EG and, therefore, facilitating shedding under pathological
circumstances [69]. MMPs are calcium-dependent zinc-con-
taining endopeptidases that play an important role in tissue
remodeling associated with morphogenesis, angiogenesis,
wound healing, arthritis, and cancer [112, 124]. Once activat-
ed, MMPs degrade extracellular matrices (collagen, elastin,
gelatin), induce cell migration by providing directional cues,
create substrate-cleavage fragments, coordinate tissue archi-
tecture, and modify the activity of signaling molecules
[113]. Specifically, MMP-2,MMP-7, andMMP-9 are capable
of directly cleaving chondroitin sulfate [49] and MMP-1
cleaves the heparan sulfate proteoglycan syndecan-1 [35].
MMP-9 is also the major sheddase of syndecan-4 in glomer-
ular endothelial cells in the setting of diabetic nephropathy
[102]. Most importantly, both the active and proactive forms
of MMP-2 and MMP-9 are stored in the vesicular compart-
ment within endothelial cells, suggesting the existence of
mechanisms by which MMPs can be rapidly released by these
cells [117].
An additional important contributor to shedding of the EG is
heparanase. Heparanase cleaves the glycosidic bond within the
heparan sulfate chain at specific sites. It is synthesized as a pre-
proheparanase, processed to proheparanase at the endoplasmic
reticulum, and transported to the Golgi apparatus, where it is
packaged into vesicles and finally secreted [46]. After secretion,
heparanase interacts with cell membrane heparan sulfate pro-
teoglycans (especially with syndecans), low density lipoprotein
receptor-related proteins, and mannose 6-phosphate receptors
[44]. Heparanase is involved in pathologic processes in tumor
growth, angiogenesis, metastasis, inflammation, and glomeru-
lar diseases [88]. During the investigation of inflammatory set-
tings, like vascular damage or rheumatoid arthritis, it has been
discovered that heparanase expression occurs mainly in the
epithelial and/or endothelial compartment [3, 46, 68] and is
induced by inflammatory cytokines [21, 29, 61, 66, 107]. Its
main mechansims during inflammation is a result of neutrophil
recruitment and the modulation of proinflammatory macro-
phage action. The induction of heparanase by inflammatory
cytokines leads to the loss of the EG and therefore to endothelial
hyperpermeability resulting in a higher amount of extravasation
of neutrophils [104, 107]. However, there are also reports of
high levels of heparanase resulting in a decreased amount of
extravasation of neutrophils [67, 104]. Increased levels of
heparanase also result in a decreased level of cell-surface hep-














Fig. 2 Endothelial Sirtuin1-deficiency leads to the degradation of the
endothelial glycocalyx. Endothelial Sirtuin1-deficiency, a model of glob-
al endothelial dysfunction, leads on the one hand to increase NF-κB
signaling and on the other hand causes increased oxidative stress. The
increased NF-κB signaling induces both the transcription of syndecan-4
and heparanase. In addition to that NF-κB reduces Sirtuin1-activity and
therefore sustaining the endothelial cell dysfunction. The increased oxi-
dative stress induces ADAM17-acitivity which results in a greater
amount of shedding of syndecan-4. The higher shedding of syndecan-4
and the higher activity of heparanase cause the degradation of the endo-
thelial glycocalyx. Furthermore, the shed ectodomain of syndecan-4
gains systemic effects and potentiates a pro-fibrogenic response
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therefore increasing the activation of macrophages [16, 66].
The enzymatic activity of heparanase is well studied in multiple
myeloma. Patients suffering from multiple myeloma were
found to have an increased level of heparanase in the bone
marrow plasma [61, 86], and over 90% of multiple myeloma
patients had increased heparanase expression in gene array
analysis [75].
Notably, during the progression of chronic kidney disease,
heparanase exerts an important contributing role through its
participation in renal fibrogenesis via controlling the
epithelial-mesenchymal transition in renal tubular cells [79].
A recent study performed by Masola et al. showed protection
against chronic kidney dysfunction by inhibiting heparanase
[77]. Abassi et al. showed in their experiments more profound
renal injuries in the ischemic reperfusion model in heparanase-
overexpressing (Hpa-tg) mice [1]. They also demonstrated a
higher number of biomarkers of epithelial mesenchymal transi-
tion in Hpa-tg mice, suggesting heparanase to be of importance
in the process of kidney fibrosis. An assumption which the
same group corroborated in a study shows high levels of epi-
thelial mesenchymal transition markers in wild-type mice, but
no significant increase in those markers in heparanase-silenced
tubular cells of the kidney [78]. As heparanase is also involved
in the development of acute experimental glomerulonephritis
via reinforcing renal leukocyte and macrophage influx by
shrinking the heparan sulfate expression at the glomerulus
[42], it is a great target for further clinical investigation.
Another type of sheddase is hyaluronidase. Hyaluronidase
cleaves hyaluronan, a high-molecular weight, unsulfated gly-
cosaminoglycan which is highly enriched on the apical sur-
face of endothelial cells [30, 52]. It has been shown that there
is an association between an increased hyaluronanmetabolism
and structural changes of the arterial wall with accelerated
atherogenesis in type 1 diabetes as a result of heightened ac-
tivity of hyaluronidase [89]. Furthermore, hyaluronidase has
been implicated as a marker for various cancers, such as gen-
itourinary, colorectal, or breast cancer [31, 65, 81, 96].
Because of being an inducer of pro-tumorigenic and pro-
angiogenic phenotypes, therapeutic approaches targeting hy-
aluronidase are under intense investigation. So far partially
sulfated hyaluronic acid polymers have been the only hyal-
uronidase inhibitors to be tested in an in vivo model. Benitez
et al. showed delayed tumor growth in mice suffering of pros-
tate cancer [7]. HA shed by hyaluronidase and measured in the
plasma or urine is considered to be a marker of the integrity of
the EG during sepsis, ischemia/reperfusion, and diabetes [26].
Important participants in the process of shedding of the EG
are members of the ADAM family. The ADAM gene family
is a member of a metalloproteinase superfamily, which in-
cludes a diverse group of multi-domain transmembrane and
secreted proteins with a variety of biological functions. The
main function of ADAM proteins is to regulate shedding of
the extracellular domains of several proteins, such as tumor
necrosis factor-α (TNFα) receptor, Notch, or transforming
growth factor-α (TGFα) [14]. Specifically, ADAM17 has
been shown to be involved in the degradation of the EG by
shedding the ectodomain of syndecan-4 [94]. ADAM17 con-
sists of three different domains: the prodomain, the catalytic
domain, and the cytoplasmic domain. The catalytic domain is
responsible for shedding and therefore it is the target structure
for inhibition of ADAM17 [48]. ADAM17 has been implicat-
ed in a variety of diseases. As a TNFα-receptor-cleaving en-
zyme, ADAM17 has been shown to be upregulated in inflam-
matory diseases like rheumatoid arthritis or psoriasis [59, 92].
Because of its ability to shed growth factors, which are nec-
essary for tumor growth and progression, ADAM17 has been
reported to contribute to the development of a malignant phe-
notype [48]. Indeed, ADAM17 has been found to be
overexpressed in breast and ovarian tumors [11, 116].
Involvement of ADAM17 in the setting of diabetes is most
likely due to TNFα-activation through ADAM17 since treat-
ment with an ADAM17 inhibitor improves insulin sensitivity
[120]. In the context of the present discussion, ADAM17 ac-
tivity is redox-dependent and oxidative stress enhances it
[128]. Notably, renal microvascular endothelial cells isolated
from SIRT1endo-/- mice exhibit a significant increase in basal
and inducible generation of superoxide [73], thus potentially
explaining the elevated activity of ADAM17 in these cells.
Having listed the sheddases with the known specific
targeting of the EG, the question arises if inhibition of these
enzymes could preserve the integrity of the EG. For instance,
experimental studies revealed protection by antithrombin
against shedding of the EG under ischaemic and inflammatory
conditions [19]. The antithrombin molecule consists of a bind-
ing domain for heparin and heparan, which is responsible for
its anti-inflammatory effects, besides inhibiting serine prote-
ases [127]. In other words, antithrombin prevents degradation
of the endothelial glycocalyx, because of a tight binding to
heparan sulfate proteoglycans and, therefore, blocking access
of sheddases.
A different approach would be to inhibit the above men-
tioned sheddases directly. In a clinical study, inhibition of
ADAM17 reduced the presence of the epidermal growth fac-
tor receptor ligand TGF-α, which is incriminated in renal fi-
brosis. Therefore, inhibition of ADAM17 has the potential to
intervene in human renal diseases [82]. Furthermore, Hu et al.
showed that intravenous injection of a MMP-9 inhibitor pro-
tects mice against lethal endotoxin shock [54]. Zeng et al.
demonstrated protection of the EG through sphingosine-1-
phosphate mediated inhibition of syndecan-1 shedding [132].
Summary
In summary, endothelial SIRT1-deficiency, a model of global
endothelial dysfunction, leads to upregulation of syndecan-4
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and release of its ectodomain, the loss of the EG through
increased superoxide generation and induced NF-κB signal-
ing. Furthermore syndecan-4, a major proteoglycan compo-
nent of the EG and a binding partner of glycosaminoglycans
comprising this structure are shed to a greater extent and its
released ectodomain acts as a pro-fibrotic molecule, coordi-
nating the inflammatory and pro-fibrogenic responses after
applied damage to the endothelium and the consequent loss
of the EG. The data and arguments presented herein provide a
tentative outline of a potentially new target of SIRT1, endo-
thelial glycocalyx, and emphasize the role of defective SIRT1
deacetylation in glycocalyx degradation.
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